NextCure, Inc. (NXTC)
NASDAQ: NXTC · Real-Time Price · USD
1.645
-0.005 (-0.30%)
At close: Jun 26, 2026, 4:00 PM EDT
1.640
-0.005 (-0.30%)
After-hours: Jun 26, 2026, 7:55 PM EDT
NextCure Stock Forecast
NXTC's stock price has decreased by -70.59% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 2 analysts with 12-month price forecasts for NextCure stock have an average target of 20, with a low estimate of 15 and a high estimate of 25. The average target predicts an increase of 1,115.81% from the current stock price of 1.65.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for NextCure stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Mar '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $15 | Buy | Maintains | $15 | +811.85% | Jun 11, 2026 |
| Lucid Capital | Lucid Capital | Buy Maintains $25 | Buy | Maintains | $25 | +1,419.76% | Jun 2, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-7.32
from -19.65
EPS Next Year
-8.31
from -7.32
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | n/a | n/a | |
| Avg | n/a | n/a | |
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2027 | 2028 |
|---|---|---|
| High | - | - |
| Avg | - | - |
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -6.17 | -5.49 | |
| Avg | -7.32 | -8.31 | |
| Low | -8.11 | -10.41 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.